Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, said Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University.
Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University, said at the 56th ASH Annual Meeting in San Francisco, December 6-9, 2014.
“Then the question was: ‘What can we do with those differences?’” she said.
Now that they know how stem cells behave, they can understand how cancer stem cells communicate differently with their environment and identify which of the hundred of changes are fueling the cancer.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More